

Match Overview

- 1** **Internet** 13 words
crawled on 14-Mar-2020
www.thieme-connect.com <1%
- 2** **Crossref** 12 words
B.R. Hemmelgarn, J. Zhang, B.J. Manns, M. Tonelli et al. "P...
gression of kidney dysfunction in the community-dwelling elde <1%
- 3** **Internet** 12 words
crawled on 13-Mar-2019
journals.sagepub.com <1%

Name of Journal: *World Journal of Clinical Oncology*

Manuscript NO: 61561

Manuscript Type: CASE REPORT

Lenvatinib-induced multiorgan adverse events in Hurthle cell thyroid cancer: A case report

Lenvatinib-induced adverse events in thyroid cancer

Abstract

BACKGROUND

The management of metastatic progressive radioiodine-resistant differentiated thyroid cancer remains challenging for clinicians. The availability of tyrosine kinase inhibitors (TKIs), sorafenib and lenvatinib, within the last decade has expanded treatment options; however, these lead to significant adverse effects, which may curtail their use.

CASE SUMMARY



ALL

IMAGES

VIDEOS

4,800 Results

Any time ▾

[Lenvatinib in Management of Solid Tumors - Hao - 2020 ...](#)

<https://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2019-0407>

Oct 14, 2019 · Lenvatinib Use and Approval in Solid Tumors Differentiated Thyroid Cancer. Initially, in a phase II trial enrolling 58 patients, lenvatinib showed robust activity in advanced, radiation-refractory differentiated thyroid cancer (RR-DTC; papillary, follicular, or Hurthle cell).

Cited by: 5

Author: Zhonglin Hao, Zhonglin Hao, Peng Wang,...

Publish Year: 2020

[Lenvatinib in Advanced Radioiodine-Refractory Thyroid ...](#)

<https://www.jcancer.org/v09p0250.htm> ▾

Another meta-analysis focussing on AEs of lenvatinib reported in the 14 currently published clinical trials reported involved a total number of 978 patients predominantly with thyroid cancer and renal cell carcinoma . The most frequent grade ≥ 3 treatment-related adverse events were thrombocytopenia, hypertension, peripheral edema and increased aspartate aminotransferase levels.

[\(PDF\) Treatment and surveillance of advanced, metastatic ...](#)

<https://www.researchgate.net/publication/313186823...>

adverse events seen with lenvatinib. Serious ... et al. Solitary liver metastasis from Hurthle cell. thyroid cancer: a case report and review of the literature.

[Lenvatinib in Advanced Radioiodine-Refractory Thyroid ...](#)

<https://www.researchgate.net/publication/322191773...>

The objective of this review is to give an update on MKI treatment (lenvatinib, sorafenib, sunitinib, cabozantinib, pazopanib, vandetanib) of thyroid cancer, regarding its efficacy and safety profile.

[Clinical guidance for radioiodine refractory ...](#)

<https://onlinelibrary.wiley.com/doi/10.1111/cen.13508>

R.C.-B. has received honoraria for lectures on thyroid cancer, including use of kinase inhibitors, from Eisai. D.J.T and B.G.R were principal investigators for the SELECT trial of lenvatinib, and for ongoing trials of lenvatinib in thyroid cancer. Other authors had no conflicts of interest to declare.

Cited by: 8

Author: Matti L. Gild, Matti L. Gild, Duncan J. Top...

Publish Year: 2018

国内版

国际版

Microsoft Bing

Lenvatinib-induced multiorgan adverse events in Hurthle cell thyroid



ALL

IMAGES

VIDEOS

12,100 Results

Any time ▼

Solitary liver metastasis from Hürthle cell thyroid cancer ...

<https://www.researchgate.net/publication/8648435...>

Request PDF | Solitary liver metastasis from Hürthle **cell thyroid cancer: A Case Report and review** of the **literature** | Metastasis to the liver from **thyroid cancer** is a rare **event** ...

Lenvatinib in Advanced Radioiodine-Refractory Thyroid ...

<https://www.researchgate.net/publication/322191773...>

Purpose:Differentiated **thyroid cancer** (DTC) accounts for approximately 95% of **thyroid** carcinomas. In the metastatic RAI-refractory disease, chemotherapy has ...

(PDF) Neoadjuvant Therapy in Differentiated Thyroid Cancer

https://www.researchgate.net/publication/308574202_Neoadjuvant_Therapy_in...

Hurthle cell thyroid cancer. ... **case** reports in order to enhance the current data for this. treatment. ... reductions due to **adverse events**, the most common (of any.

(PDF) Lenvatinib, a molecule with versatile application ...

<https://www.researchgate.net/publication/332796899...>

Lenvatinib is an emerging multi-kinase inhibitor with a preferential anti-angiogenic activity, which has shown efficacy in the treatment of renal **cell** carcinoma, differentiated **thyroid cancer** and ...

Multikinase inhibitors in the treatment of thyroid cancer ...

<https://www.researchgate.net/publication/261766610...>

The purpose of this paper is to **review** the development of targeted agents for **thyroid** malignancy, with a special focus on lenvatinib, a multikinase inhibitor. Main studies in advanced **thyroid**

Microsoft Bing

Lenvatinib-induced multiorgan adverse events in Hurthle cell th

ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

12,200 Results

Any time ▾

Lenvatinib versus Placebo in Radioiodine-Refractory ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1406470>

Adverse effects were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, ... or Hürthle-cell thyroid cancer), thyrotropin level (≤0.5, >0.5 to 2 ...

Cited by: 1085

Author: Martin Schlumberger, Makoto Tahara, L...

Publish Year: 2015

Lenvatinib in Advanced Radioiodine-Refractory Thyroid ...

<https://www.researchgate.net/publication/322191773...>

Hurthle cell), or poorly differentiated. ... in a 65-year-old man with recurrent thyroid cancer. Case presentation: The patient was admitted to our department following a complaint of acute-onset ...

PEOPLE ALSO ASK

Can Lenvatinib cause thyroid cancer?

What is the adverse effect of Lenvatinib?

Are differentiated thyroid nodules common?

What is the survival rate for thyroid cancer?

Feedback

Medication-related osteonecrosis of the jaw in a cancer ...

<https://www.researchgate.net/publication/334885842...>

The aim of this article was to describe an original case of lenvatinib-related osteonecrosis of the jaw in a patient affected by thyroid cancer. A 58-year-old man diagnosed with Hurthle cell ...

Three Cases of Anaplastic Thyroid Carcinoma Transformation ...

<https://www.hindawi.com/journals/crie/2020/6667237> ▾

Since 2015, the cancer treatment lenvatinib has been used for patients with advanced radioactive iodine- (RAI-) refractory thyroid differentiated cancer; however, the drug's long-term effects have